Previous studies have shown a link between low vitamin D status and heart disease. Now a new study shows that patients with high blood pressure who possess a gene variant that affects an enzyme critical to normal vitamin D activation are twice as likely as those without the variant to have congestive heart failure.
"This study is the first indication of a genetic link between vitamin D action and heart disease," says Robert U. Simpson, professor of pharmacology at the University of Michigan Medical School and one of the authors of the study in the journal Pharmacogenomics.
"This study revealed that a critical enzyme absolutely required for production of the vitamin D hormone has a genetic variant associated with the development of congestive heart failure," Simpson says. "If subsequent studies confirm this finding and demonstrate a mechanism, this means that in the future, we may be able to screen earlier for those most vulnerable and slow the progress of the disease." Such a screening test would be years away.
Study co-authors Russel A. Wilke of the Medical College of Wisconsin and Catherine A. McCarthy of the Marshfield Clinic Research Foundation in Marshfield, Wis., analyzed the genetic profiles of 617 subjects from the Marshfield Clinic Personalized Medicine Project, a large DNA biobank. They looked for variants in five candidate genes chosen for their roles in vitamin D regulation and hypertension. One-third of the subjects had both hypertension and congestive heart failure, one-third had hypertension alone and one-third were included as healthy controls.
The results showed that a variant in the CYP27B1 gene was associated with congestive heart failure in patients with hypertension. It is already known that mutations that inactivate this gene reduce the required conversion of vitamin D into an active hormone.
"This initial study needs to be confirmed with a larger study that would permit analysis of the full cardiovascular profile of the population possessing the gene variant," Simpson says. A future study also would need to include people of more diverse origins than this study's population of mostly European ancestry, the authors say.
Citation: Pharmacogenomics, (2009) 10(11):1789-97
Additional authors: Bikol N. Mukesh, Satya V. Bhupathi, Richard A. Dart and Nader R. Ghebranious, Center for Human Genetics, Marshfield Clinic Research Foundation
Funding: National Institutes of Health, Marshfield Clinic Personalized Medicine Research Project, Abbott Laboratories, Michigan Institute for Clinical and Health Research
Patents/conflict disclosures: The research was funded in part by donors to cardiology research at Marshfield Clinic. Robert Simpson has a financial interest in and is president of Cardiavent, Inc., a company that is developing an analog (CARDO24) of vitamin D to treat cardiovascular diseases.
Anne Rueter | EurekAlert!
The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences